451 related articles for article (PubMed ID: 20601976)
1. Osmium(II)--versus ruthenium(II)--arene carbohydrate-based anticancer compounds: similarities and differences.
Hanif M; Nazarov AA; Hartinger CG; Kandioller W; Jakupec MA; Arion VB; Dyson PJ; Keppler BK
Dalton Trans; 2010 Aug; 39(31):7345-52. PubMed ID: 20601976
[TBL] [Abstract][Full Text] [Related]
2. From hydrolytically labile to hydrolytically stable Ru(II)-arene anticancer complexes with carbohydrate-derived co-ligands.
Hanif M; Meier SM; Kandioller W; Bytzek A; Hejl M; Hartinger CG; Nazarov AA; Arion VB; Jakupec MA; Dyson PJ; Keppler BK
J Inorg Biochem; 2011 Feb; 105(2):224-31. PubMed ID: 21194622
[TBL] [Abstract][Full Text] [Related]
3. Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions.
Peacock AF; Habtemariam A; Fernández R; Walland V; Fabbiani FP; Parsons S; Aird RE; Jodrell DI; Sadler PJ
J Am Chem Soc; 2006 Feb; 128(5):1739-48. PubMed ID: 16448150
[TBL] [Abstract][Full Text] [Related]
4. Tuning the hydrolytic aqueous chemistry of osmium arene complexes with N,O-chelating ligands to achieve cancer cell cytotoxicity.
Peacock AF; Parsons S; Sadler PJ
J Am Chem Soc; 2007 Mar; 129(11):3348-57. PubMed ID: 17319668
[TBL] [Abstract][Full Text] [Related]
5. Amide linkage isomerism as an activity switch for organometallic osmium and ruthenium anticancer complexes.
van Rijt SH; Hebden AJ; Amaresekera T; Deeth RJ; Clarkson GJ; Parsons S; McGowan PC; Sadler PJ
J Med Chem; 2009 Dec; 52(23):7753-64. PubMed ID: 19791745
[TBL] [Abstract][Full Text] [Related]
6. Organometallic osmium(II) arene anticancer complexes containing picolinate derivatives.
van Rijt SH; Peacock AF; Johnstone RD; Parsons S; Sadler PJ
Inorg Chem; 2009 Feb; 48(4):1753-62. PubMed ID: 19146436
[TBL] [Abstract][Full Text] [Related]
7. Anticancer activity of opened arene ruthenium metalla-assemblies.
Barry NP; Zava O; Furrer J; Dyson PJ; Therrien B
Dalton Trans; 2010 Jun; 39(22):5272-7. PubMed ID: 20442944
[TBL] [Abstract][Full Text] [Related]
8. Selenoquinones stabilized by ruthenium(II) arene complexes: synthesis, structure, and cytotoxicity.
Dubarle-Offner J; Clavel CM; Gontard G; Dyson PJ; Amouri H
Chemistry; 2014 May; 20(19):5795-801. PubMed ID: 24668791
[TBL] [Abstract][Full Text] [Related]
9. Is the reactivity of M(II)-arene complexes of 3-hydroxy-2(1H)-pyridones to biomolecules the anticancer activity determining parameter?
Hanif M; Henke H; Meier SM; Martic S; Labib M; Kandioller W; Jakupec MA; Arion VB; Kraatz HB; Keppler BK; Hartinger CG
Inorg Chem; 2010 Sep; 49(17):7953-63. PubMed ID: 20704358
[TBL] [Abstract][Full Text] [Related]
10. Highly active neutral ruthenium(II) arene complexes: synthesis, characterization, and investigation of their anticancer properties.
Ludwig G; Kaluđerović GN; Bette M; Block M; Paschke R; Steinborn D
J Inorg Biochem; 2012 Aug; 113():77-82. PubMed ID: 22698819
[TBL] [Abstract][Full Text] [Related]
11. Anticancer activity of osmium metalla-rectangles.
Barry NP; Edafe F; Dyson PJ; Therrien B
Dalton Trans; 2010 Mar; 39(11):2816-20. PubMed ID: 20200707
[TBL] [Abstract][Full Text] [Related]
12. Ruthenium(II) arene anticancer complexes with redox-active diamine ligands.
Bugarcic T; Habtemariam A; Deeth RJ; Fabbiani FP; Parsons S; Sadler PJ
Inorg Chem; 2009 Oct; 48(19):9444-53. PubMed ID: 19780621
[TBL] [Abstract][Full Text] [Related]
13. Ruthenium(II) and osmium(II) 1,2,3-triazolylidene organometallics: a preliminary investigation into the biological activity of 'click' carbene complexes.
Kilpin KJ; Crot S; Riedel T; Kitchen JA; Dyson PJ
Dalton Trans; 2014 Jan; 43(3):1443-8. PubMed ID: 24201979
[TBL] [Abstract][Full Text] [Related]
14. Chloro half-sandwich osmium(II) complexes: influence of chelated N,N-ligands on hydrolysis, guanine binding, and cytotoxicity.
Peacock AF; Habtemariam A; Moggach SA; Prescimone A; Parsons S; Sadler PJ
Inorg Chem; 2007 May; 46(10):4049-59. PubMed ID: 17441712
[TBL] [Abstract][Full Text] [Related]
15. Organometallic osmium arene complexes with potent cancer cell cytotoxicity.
Fu Y; Habtemariam A; Pizarro AM; van Rijt SH; Healey DJ; Cooper PA; Shnyder SD; Clarkson GJ; Sadler PJ
J Med Chem; 2010 Nov; 53(22):8192-6. PubMed ID: 20977192
[TBL] [Abstract][Full Text] [Related]
16. In vitro anticancer activity and biologically relevant metabolization of organometallic ruthenium complexes with carbohydrate-based ligands.
Berger I; Hanif M; Nazarov AA; Hartinger CG; John RO; Kuznetsov ML; Groessl M; Schmitt F; Zava O; Biba F; Arion VB; Galanski M; Jakupec MA; Juillerat-Jeanneret L; Dyson PJ; Keppler BK
Chemistry; 2008; 14(29):9046-9057. PubMed ID: 18688905
[TBL] [Abstract][Full Text] [Related]
17. The contrasting chemistry and cancer cell cytotoxicity of bipyridine and bipyridinediol ruthenium(II) arene complexes.
Bugarcic T; Habtemariam A; Stepankova J; Heringova P; Kasparkova J; Deeth RJ; Johnstone RD; Prescimone A; Parkin A; Parsons S; Brabec V; Sadler PJ
Inorg Chem; 2008 Dec; 47(24):11470-86. PubMed ID: 19007206
[TBL] [Abstract][Full Text] [Related]
18. Use of chelating ligands to tune the reactive site of half-sandwich ruthenium(II)-arene anticancer complexes.
Fernández R; Melchart M; Habtemariam A; Parsons S; Sadler PJ
Chemistry; 2004 Oct; 10(20):5173-9. PubMed ID: 15372674
[TBL] [Abstract][Full Text] [Related]
19. Development of bimetallic titanocene-ruthenium-arene complexes as anticancer agents: relationships between structural and biological properties.
Pelletier F; Comte V; Massard A; Wenzel M; Toulot S; Richard P; Picquet M; Le Gendre P; Zava O; Edafe F; Casini A; Dyson PJ
J Med Chem; 2010 Oct; 53(19):6923-33. PubMed ID: 20822096
[TBL] [Abstract][Full Text] [Related]
20. Ruthenium(II)-arene complexes with functionalized pyridines: synthesis, characterization and cytotoxic activity.
Grgurić-Sipka S; Ivanović I; Rakić G; Todorović N; Gligorijević N; Radulović S; Arion VB; Keppler BK; Tesić ZLj
Eur J Med Chem; 2010 Mar; 45(3):1051-8. PubMed ID: 20053483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
